Raymond Limited has approved a preferential issue of convertible warrants — the board cleared raising up to ~₹214.71 crore by issuing 33,28,686 warrants at ₹645 each to a single investor, Minerva Ventures Fund. It is a fundraise, but an unusual kind: nobody gets new shares today, and the money arrives in two instalments.

What was announced

Raymond's board met on 8 September 2026 (3:30–3:55 pm) and filed the outcome with BSE and NSE the same evening. The approved terms:

• Instrument: 33,28,686 convertible warrants, issued for cash
• Price: ₹645 per warrant (₹10 face value + ₹635 premium)
• Total size: up to approximately ₹214.71 crore
• Allottee: Minerva Ventures Fund — one investor, on a private placement basis, under Chapter V of the SEBI ICDR Regulations
• Conversion: each warrant carries the right to subscribe to 1 equity share at ₹645, exercisable in one or more tranches within a maximum of 18 months from allotment
• Forfeiture: unconverted warrants lapse after 18 months and the upfront money paid on them is forfeited
• Stake: Minerva holds zero shares today; after full conversion it would hold 4.35% on a fully diluted basis

The issue is still subject to shareholder approval and other statutory and regulatory clearances. It is not done yet.

What this type of filing means

Two concepts are stacked here, and they are worth separating.

A preferential issue is when a company sells new securities to a specific, named party rather than to the public. It is fast — no prospectus, no book-building — which is why companies use it when they want capital from one investor. In exchange for that speed, SEBI regulates it tightly: a minimum price formula, a lock-in on the securities, and a shareholder vote.

A convertible warrant is not a share. It is a right to buy a share later at a price fixed today. Under SEBI's ICDR rules the investor pays at least 25% of the price upfront and the remaining balance only when they actually convert; the filing itself does not break out that split. So the investor is buying an 18-month option, and paying a non-refundable deposit for it. If Raymond's shares are above ₹645 when the window closes, converting is obviously worth it. If they are well below, the investor can simply walk away and forfeit the upfront money.

That structure matters for you as a shareholder: the dilution is deferred and conditional, not immediate. No new shares exist until conversion happens.

Why the price says ₹645 when the stock is near ₹858

This is the part that confuses most people, so it is worth understanding properly. The warrants are priced at ₹645 while the stock has been trading around ₹858 — roughly a 25% discount to market. That is not a favour to the investor; it is arithmetic.

SEBI's ICDR pricing formula sets a floor price based on the volume-weighted average price over a trailing window (the higher of the 90-trading-day and 10-trading-day VWAP), not on yesterday's close. Raymond's stock rose sharply into this announcement — Business Today reported it climbing 9.6% on 8 September, from a previous close of ₹772.80 to a 52-week high of ₹847.35, and trading around ₹858.35 on 9 September. A trailing average simply has not caught up with a move that recent.

So a wide gap between the issue price and the market price usually tells you the stock has run up fast, not that the company is handing out a bargain. The lock-in period on preferentially issued securities exists precisely to stop an investor from pocketing that gap immediately.

Why it matters / potential impact

• Size is modest. Against Raymond's market capitalisation of roughly ₹5,708 crore (Screener.in), a ₹214.71 crore raise is under 4%. This is not a balance-sheet rescue; it reads as growth or expansion capital.
• Dilution is capped and known. 4.35% fully diluted is the maximum, and only if the investor converts everything. Existing shareholders can size that risk precisely.
• A single outside investor is buying in. Minerva Ventures Fund currently owns nothing. One investor willing to commit at a fixed price for 18 months is a signal about how that investor views the company — though it is one fund's view, not a verdict.
• Cash arrives in stages. Raymond does not receive ₹214.71 crore now. It receives the upfront portion, and the rest only if and when conversion happens — so any capex plan funded by this has a timing dependency.
• The filing does not say what the money is for. That is a genuine gap. Watch the shareholder notice (the postal ballot or EGM document) — that is where the stated objects of the issue must appear.

Is it expensive?

Raymond Limited trades at a P/E of about 33.9 with a market capitalisation of roughly ₹5,708 crore, and a price-to-book of about 2.0x against a book value near ₹427 per share (Screener.in). For a small-cap engineering business, a P/E in the low 30s is full but not extreme — it prices in continued growth without assuming heroics.

Compare it to a named listed peer in overlapping territory: Bharat Forge, the Kalyani Group forgings and auto-components maker with a defence arm, trades at a P/E of roughly 93.7 on a market capitalisation of about ₹94,578 crore, at close to 10x book (Screener.in). Bharat Forge is around 16 times Raymond's size and carries a far richer multiple.

Read that honestly, in both directions. Raymond looks cheap relative to Bharat Forge — but Bharat Forge is a much larger, longer-established platform, and a lower multiple on a smaller, recently restructured company is normal rather than a discovered bargain. Two companies at different scales with different track records are not supposed to trade at the same multiple. This is context, not a recommendation.

The business

This is important, because "Raymond" no longer means what most people assume. The familiar suiting-and-apparel business was demerged into the separately listed Raymond Lifestyle, and the Thane real-estate business into the separately listed Raymond Realty. What remains inside Raymond Limited is an engineering company, operating in two segments (Q1 FY27 figures):

• Precision Technology & Auto Components (JK Maini Precision Technology) — revenue ₹444 crore, EBITDA ₹61 crore, margin 13.8%, revenue up 11.5% year-on-year. This is the larger segment.
• Aerospace & Defence (JK Maini Global Aerospace) — revenue ₹123 crore, EBITDA ₹26 crore, margin 21.2%, revenue up 40.4% year-on-year. Smaller, faster-growing, higher-margin.

So a fundraise at Raymond Limited today is capital for an auto-components and aerospace manufacturer — it has nothing to do with suits or with the Thane property projects, which now sit in different listed companies with their own shareholders.

Beginner takeaway

A preferential issue of warrants is a company selling one investor the right to buy shares later at a price fixed today. Nothing is diluted yet, the money comes in two parts, and the deal can still lapse — so treat it as a conditional commitment rather than a completed fundraise. The most useful next document is not this filing but the shareholder notice, which has to state what the money will be used for.

FAQ

Do I lose value as an existing shareholder right now? No new shares have been issued yet. If the investor converts everything, they would hold 4.35% on a fully diluted basis — that is the ceiling on dilution from this issue.

Why would a company sell shares at ₹645 when the market price is around ₹858? Because SEBI's pricing formula uses a trailing volume-weighted average price, not the latest close. A stock that has risen sharply in recent sessions will often have a formula floor price well below its current market price.

What happens if the investor never converts? The warrants lapse after 18 months and the upfront amount they paid is forfeited to the company. Raymond keeps that money and issues no shares.

Is this deal final? No. It needs approval from Raymond's shareholders plus other statutory and regulatory approvals before allotment can happen.

As of 9 September 2026. Source: official BSE/NSE filing — read it directly here. We summarise filings for education and may make errors, so always verify against the official document. Educational content only — not investment advice, not a buy/sell recommendation.